As additional trials report, the picture of retatrutide efficacy and safety across different populations and indications will become increasingly complete
2022 for retatrutide, Carmona et al
There may be a day in the future in the next decade or so where people are taking lower doses of GLP-1 receptor agonists to slow the progression of osteoarthritis throughout their body. But GLP-1s alone are not enough for long-term change, especially for patients who are unable to remain on the medications due to adverse effects, cost or lack of access, according to Prather
The choice of weight loss medication will depend on several factors, like your medical history, your current health status, and weight loss goals
The current narrative on these new peptides is being predominantly shaped by influencers and social media supplement sellers, whose main motivation is often profit over any form of patient safety